Biopharmaceutical firm Biocon Ltd announced the launch of its Glucagon-like Peptide-1 (GLP-1) analog, Liraglutide, in the United Kingdom (U.K.). The drug is used for the treatment of diabetes and obesity. This launch follows the nod from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the first generics company to receive approval for […]
Biocon shares end 5% higher after US drug regulator clears Bengaluru API unit – CNBC TV18
Shares of Biocon extended gains on Tuesday, December 24 after the United States Food and Drug Administration (USFDA) issued an Establishment Inspection Report (EIR) with a Voluntary Action Status (VAI) for its Active Pharmaceutical Ingredients (API) facility in Bengaluru. Company Value Change %Change The EIR with the VAI status was for the site 1 of […]
Biocon EPS estimates cut by 38% by Nuvama who sees challenges for Sun Pharma, Cipla – CNBC TV18
Brokerage firm Nuvama has cut Biocon Ltd.’s Earnings Per Share (EPS) estimates by 38% for financial year 2025 as it expects struggles for the company’s generics business. A USFDA clearence to the Bengaluru unit, litigation outcome of the Aflibercept, a reinspection of the Malaysia unit and financial deleveraging along with a recovery in Syngene and […]